REG - Aptamer Group PLC - Issue of Equity in lieu of Non-Exec Director Fees

AptamerAnnouncement

18/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250718:nRSR5713Ra&default-theme=true

RNS Number : 5713R  Aptamer Group PLC  18 July 2025

 

18 July 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Issue of Equity in lieu of Non-Executive Director Fees

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life sciences industry, today
announces that it has issued 2,968,695 new ordinary shares of 0.1 pence each
("Ordinary Shares") at an average issue price of 0.3368 pence per Ordinary
Share to settle Non-Executive Director fees.

 

Director Fee Shares

 

Tim Sykes has agreed to take shares in lieu of his Non-Executive Director
fees, to be issued to him on a quarterly basis. Today's share issue will cover
the period 1 April 2025 to 30 June 2025, and the price of the share issue is
based on the volume weighted average daily closing share price for the
relevant quarter.

 

Following this transaction, Tim Sykes' total beneficial interest in the
Company is 11,639,758 Ordinary Shares, representing approximately 0.49% of the
Company's issued share capital.

 

Total Voting Rights

 

An application will be made for the admission of these shares to trading on
AIM, which is expected to become effective on or around 24 July 2025.

 

Immediately following Admission, the Company will have 2,394,731,620 ordinary
shares of £0.001 each in issue.  The Company does not hold any shares in
treasury, and all of the Ordinary Shares have equal voting rights. Therefore,
the figures above represent the total voting rights in the Company and may be
used by shareholders as the denominator for the calculations by which they can
determine if they are required to notify their interest in, or a change to
their interest in the Company under the Rules.

 

Additional Information

 

The following disclosures are made in accordance with the requirements of the
UK Market Abuse Regulation and provide detail in relation to the purchase of
ordinary shares by directors and other PDMRs in the Company.

 

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Tim Sykes

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Aptamer Group plc

 b)   LEI                                                          213800Y4XGH3WJNBE686

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BNRRP542

 b)   Nature of the transaction                                    Award of shares

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0.3368p   2,968,695

 

 d)   Aggregated information

      - Aggregated volume                                          2,968,695
      - Price                                                      0.3368p each

 e)   Date of the transaction                                      18 July 2025

 f)   Place of the transaction                                     Off market

 

 

d)

 

Aggregated information

- Aggregated volume

2,968,695

- Price

0.3368p each

e)

 

Date of the transaction

 

 

18 July 2025

f)

 

Place of the transaction

 

Off market

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Jade Bayat
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker
 Northstar Communications Limited - Investor Relations    +44 (0) 113 730 3896

 Sarah Hollins

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

 

About Aptamer Group plc

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBRGDRISBDGUR